Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for improving fluorouracil sensitivity and application of pharmaceutical composition

A fluorouracil and sensitivity technology, which is applied to the drug combination and the application field of the drug combination, can solve the problems of easy drug resistance and low chemotherapeutic sensitivity, and achieves the effects of improving the therapeutic efficacy and improving the chemosensitivity.

Pending Publication Date: 2020-04-10
SICHUAN PROVINCIAL PEOPLES HOSPITAL
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although 5-Fu is used as the basic drug for the first-line treatment of CRC and is recommended for combination therapy, it is still limited by low chemosensitivity and drug resistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for improving fluorouracil sensitivity and application of pharmaceutical composition
  • Pharmaceutical composition for improving fluorouracil sensitivity and application of pharmaceutical composition
  • Pharmaceutical composition for improving fluorouracil sensitivity and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] A drug combination for improving sensitivity to fluorouracil, characterized in that it includes fluorouracil and hydroxychloroquine linolenate, wherein the concentration of fluorouracil is 1.25-10 μmol / L, and the concentration of hydroxychloroquine linolenate is 10-160 μmol / L, set Fluorouracil single-drug group, hydroxychloroquine linolenate single-drug group, and fluorouracil combined with hydroxychloroquine linolenate group, wherein the ratio of fluorouracil to hydroxychloroquine linolenate in the fluorouracil combined with hydroxychloroquine linolenate group was 1:8, each group The experiment was repeated 3 times independently, and the tumor cells were added and cultured on the micro-culture plate for 24h, 48h and 72h respectively, and the data were observed and recorded.

Embodiment 2

[0018] A drug combination that increases fluorouracil sensitivity in rectal cancer.

Embodiment 3

[0020] In vitro verification:

[0021] 1. The concentration of 5-Fu single-drug group was 1.25-10 μmol / L; the concentration of AHQ single-drug group was 10-160 μmol / L; when the ratio of 5-Fu combined with AHQ group was 1:8, the action time of 48 and 72 hours could significantly improve the 5-Fu Chemosensitization of Fu on HCT116 cells leading to enhanced antitumor activity. See Table 1-3 and figure 1 .

[0022] Table 1 Inhibition rate of 5-Fu, AHQ and 5-Fu combined with AHQ on HCT116 cells for 24h (%)

[0023]

[0024]

[0025] The formula for calculating the average value of each group is ( n=3) compared with the control group: *P<0.05, **P<0.01; compared with the 5-Fu group: #P<0.05, ##P<0.01; Compared with AHQ group: $P<0.05, $$P<0.01; compared with AHQ group and 5-Fu group: &P<0.05, &&P<0.01.

[0026] Table 2 Inhibitory rate of 5-Fu, AHQ and 5-Fu combined with AHQ on HCT116 cells for 48h (%)

[0027]

[0028] The formula for calculating the average value of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for improving fluorouracil sensitivity. The pharmaceutical composition is characterized in that the pharmaceutical composition comprises fluorouracil and hydroxychloroquine linolenate, wherein the concentration of fluorouracil is 1.25 to 10 [mu] mol / L, and the concentration of hydroxychloroquine linolenate is 10 to 160 [mu] mol / L; a fluorouracilsingle-drug group, a hydroxychloroquine linolenate single-drug group and a fluorouracil combined hydroxychloroquine linolenate group are arranged; each group of experiments is independently repeatedfor three times; tumor cells are added and then are cultured on a micro-culture plate for 24 hours, 48 hours and 72 hours respectively; and data of the tumor cells are observed and recorded. The invention further discloses an application of the pharmaceutical composition for improving fluorouracil sensitivity in colorectal cancer. The pharmaceutical composition has the advantages that fluorouraciland hydroxychloroquine linolenate are combined for use, so that the chemosensitivity of fluorouracil can be improved, and the treatment effect is improved; the medication compliance of colorectal cancer patients can be improved; and meanwhile, the pain of the patients can be relieved.

Description

technical field [0001] The present invention relates to the technical field of medicine, in particular to a drug combination for improving fluorouracil sensitivity and the application of the drug combination. Background technique [0002] Colorectal cancer (CRC) is one of the leading causes of cancer death and is the second most common cancer in women and the third most common cancer in men. In recent years, the incidence of colorectal cancer in China has been increasing. In 2015 alone, 191,000 patients died in China, and its death rate ranks fifth among all cancers. The clinical treatment for CRC is mainly surgical resection of the primary tumor; and when the disease progresses or metastasizes, chemotherapy is used for treatment. Chemotherapy has been the standard treatment for clinical treatment of CRC. According to the National Comprehensive Cancer Network (NCCN) guidelines (2018 edition), the first-line treatment for advanced colorectal cancer is based on 5-fluorouraci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/513A61K31/4706A61P35/00
CPCA61K31/513A61K31/4706A61P35/00A61K2300/00
Inventor 廖治童荣生喻冬柯韩丽珠张丽娟串俊兰尹琪楠
Owner SICHUAN PROVINCIAL PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com